A COMPARATIVE STUDY OF DOXYLAMINE SUCCINATE WITH PYRIDOXINE HYDROCHLORIDE AND ONDANSETRON IN TREATING UREMIA-INDUCED NAUSEA AND VOMITING IN CHRONIC RENAL FAILURE PATIENTS

PRATIM SENGUPTA; TAPAS ROY; ATREYEE CHAUDHURI; KAVITA RATHORE

doi:10.22159/ajpcr.2023.v16i11.49658

Authors

PRATIM SENGUPTA Bellevue Clinic and ILS Group of Hospital, Kolkata, West Bengal, India.
TAPAS ROY Department of Nephrology, ILS Hospital, Dumdum, Kolkata, West Bengal, India.
ATREYEE CHAUDHURI Nephrocare India, HC96+FM, JC 18, JC Block, Sector III, Bidhannagar, Kolkata, West Bengal, India.
KAVITA RATHORE Department of Pharmacology, Ananta Institute of Medical Sciences and Research Center, Rajsamand, Rajasthan, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i11.49658

Keywords:

Doxylamine succinate-pyridoxine hydrochloride, Ondansetron, Uremia, Nausea, Vomiting, Chronic kidney disease

Abstract

Objective: Advanced-stage chronic kidney disease (CKD) patients often complain of uremic dyspeptic syndrome specifically nausea and vomiting. This is a distressing phenomenon that compromises the patients’ quality of life. There is no guideline available for a complete cure for nausea and vomiting in CKD. The objective of this study was to evaluate and compare the effect of doxylamine succinate with pyridoxine hydrochloride and routinely used ondansetron in improving the symptoms of non-dialyzed conservative CKD patients.

Methods: A randomized, open-label, comparative study was done with 70 patients in the doxylamine succinate-pyridoxine group and 65 in the ondansetron group, a total of 135 patients completed the study. The study duration was 7 days. A catboost regression on the response of area under curve matric was carried out to compare the visual analog scale (VAS) score differences. Analysis of covariance and Wilcoxon signed-rank test was used to compare biochemical parameters and quality of life (SF-36) scores of both groups.

Results: It was observed that there was a stark difference in the VAS score (nausea scale) for the non-dialysis patients in doxylamine succinate-pyridoxine hydrochloride in comparison to the ondansetron. Among the different measures of quality of life, physical function, physical role, and social function were found to be significantly improved by doxylamine succinate-pyridoxine hydrochloride as compared to ondansetron.

Conclusion: Doxylamine succinate-pyridoxine hydrochloride is frequently prescribed for pregnancy-induced nausea and vomiting but is also effective in reducing uremia-induced nausea and vomiting symptoms in conservative CKD patients.

Downloads

Download data is not yet available.

References

Lew SQ, Radhakrishnan J. Chronic kidney disease and gastrointestinal disorders. In: Kimmel PL, Rosenberg ME, editors. Chronic Renal Disease. 2nd ed. United States: Academic Press; 2020. p. 521-39. https:// doi.org/10.1016/B978-0-12-815876-0.00033-4

Asgari MR, Asghari F, Ghods AA, Ghorbani R, Motlagh NH, Rahaei F. Incidence and severity of nausea and vomiting in a group of maintenance hemodialysis patients. J Renal Inj Prev 2017;6:49.

Nand N, Malhotra P, Bala R. Evaluation of upper gastrointestinal symptoms and effect of different modalities of treatment in patients of chronic kidney disease. J Indian Acad Clin Med 2014;15:182-7.

Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F, et al. Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol 2016;4:360-73. https://doi.org/10.1016/S2213-8587(16)00033-4

Dehghani H, Heidari F, Mozaffari-Khosravi H, Nouri-Majelan N, Dehghani A. Synbiotic supplementations for azotemia in patients with chronic kidney disease: A randomized controlled trial. Iran J Kidney Dis 2016;10:351-7.

Ariffin NF, Naing L, Pisharam J, Khalil MA, Tamin N, Chong VH, et al. Appetite and gastrointestinal symptoms in end stage renal disease patients. J Clin Exp Nephrol 2016;1:1-6.

Chong VH, Tan J. Prevalence of gastrointestinal and psychosomatic symptoms among Asian patients undergoing regular hemodialysis. Nephrology 2013;18:97-103.

Johnston S. Symptom management in patients with stage 5 CKD opting for conservative management. Healthcare (Basel) 2016;4:72.

Andrews PL, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol 2014;722:108-21.

Metzger M, Abdel-Rahman EM, Boykin H, Song MK. A narrative review of management strategies for common symptoms in advanced CKD. Kidney Int Rep 2021;6:894-904.

Oliveira LG, Capp SM, You WB, Riffenburgh RH, Carstairs SD. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: A randomized controlled trial. Obstet Gynecol 2014;124:735-42. https://doi.org/10.1097/AOG.0000000000000479

Nuangchamnong N, Niebyl J. Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: An overview. Int J Womens Health 2014;6:401.

Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 2009;41:1149-60.

R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2021. Available from: https://www.R-project.org

Goodwin TM. Nausea and vomiting of pregnancy. ACOG practice bulletin no. 52. American college of obstetricians and gynecologists. Obstet Gynecol 2004;103:803-16.

Horn CC. The physiology of vomiting. In: Nausea and Vomiting: Diagnosis and Treatment. Germany: Springer; 2017. p. 15-25.

MacDougall MR, Sharma S. Physiology, chemoreceptor trigger zone. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.

Porth CM, Gaspard KJ, Noble KA. Essentials of Pathophysiology: Concept of Altered Health States. 3rd ed. Philadelphia, PA: Wolters Kluwer Health, Lippincott Williams and Wilkins; 2011.

Bruera E, Yennurajalingam S. Handbook of Hospice Palliative Medicine. United Kingdom: Oxford University Press; 2011. p. 127-34.

Ropyanto CB, Kusumaningrum NS, Hidayati W. Effects of Benson’s relaxation technique on nausea in patients with chronic kidney disease undergoing hemodialysis. KnE Life Sci 2019;4:510-9.

Vaiphei K. Gastric mucosal pathology in kidney disease. In: Interpretation of Endoscopic Biopsy-Gastritis, Gastropathies and Beyond. Germany: Springer; 2022. p. 235-6.

Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis. Eur J Pharmacol 2014;722:26-37.

Sanger GJ, Andrews PL. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front Pharmacol 2018;9:913.

Singh NN, Rai A, Selhorst JB, Acharya JN. Ondansetron and seizures. Epilepsia 2009; 50:2663-6.

Food and Drug Administration. Prescribing Information: Zofran (Ondansetron Hydrochloride). United States: Food and Drug Administration; 2009.

Capp SM, Oliveira LG, Carstairs SD, You WB. Ondansetron versus doxylamine/pyridoxine for treatment of nausea and vomiting in pregnancy: A prospective randomized double-blind trial. Clin Obstet 2014;210:S39.

Yahia MK, Khattab AO, Hamed AE. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea and vomiting in pregnancy. Int J Med Arts 2020;2:611-8. Doi: 10.21608/ ijma.2020.26371.1111

Ljutić D, Perković D, Rumboldt Z, Bagatin J, Hozo I, Pivac N. Comparison of Ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. Kidney Blood Press Res 2002;25:61-4. https://doi.org/10.1159/000049437

Gray M, Priyanka P, Kane-Gill S, Wang L, Kellum JA. Kidney and mortality outcomes associated with Ondansetron in critically ill patients. J Intensive Care Med 2022;37:1403-10. doi:10.1177/08850666211073582